RoosterBio Partners MineBio to Expand China Cell Therapy Market

RoosterBio, Inc. has entered into an exclusive distribution agreement with MineBio Life Sciences Limited to expand access to advanced cell therapy manufacturing solutions across China, a rapidly growing hub for regenerative medicine research.

Under the partnership, MineBio will distribute RoosterBio’s full portfolio of research-grade and CliniControl™ current Good Manufacturing Practice (cGMP)-grade mesenchymal stem/stromal cell (MSC) and exosome bioprocessing media. The agreement is expected to accelerate the adoption of standardized, high-quality manufacturing inputs among Chinese developers working in cell and gene therapy (CGT).

A key milestone in the collaboration is that MineBio has already secured import approval for RoosterBio’s research-use-only and cGMP-grade media products. This regulatory clearance allows immediate order fulfillment, eliminating delays that can often hinder scientific and clinical progress in the region.

China has emerged as a global leader in MSC and exosome-based research, with one of the highest numbers of active clinical trials worldwide. The country’s regenerative medicine sector has expanded rapidly in recent years, driven by strong investment, supportive policies, and a growing ecosystem of biotechnology companies and research institutions.

RoosterBio’s CliniControl™ platform is designed to support the entire lifecycle of cell therapy development—from early-stage research to full-scale cGMP manufacturing. The product suite includes MSC expansion media, exosome collection media, bioreactor feeds, and specialized media for genetic engineering applications. These tools are backed by robust regulatory documentation, including filings with the U.S. Food and Drug Administration and support for other global regulatory frameworks.

The company’s solutions have already seen broad international adoption, supporting manufacturing processes for numerous clinical trials since 2019. By partnering with MineBio, RoosterBio aims to bring this established platform to Chinese innovators, helping them streamline development timelines and improve production consistency.

MineBio’s strong presence in China’s CGT ecosystem positions it as a strategic partner for this expansion. The company maintains deep relationships across the country’s biotechnology and regenerative medicine sectors and offers expertise in navigating regulatory requirements, including those set by Chinese and international authorities.

Executives from both companies highlighted the complementary strengths of the partnership. RoosterBio emphasized MineBio’s trusted network and market expertise, while MineBio underscored the importance of scalable, regulatory-compliant manufacturing solutions to support both domestic and global clinical programs.

With operations already underway, MineBio has begun accepting and fulfilling orders, signaling an immediate impact of the collaboration. The partnership reflects a broader trend of global biotech firms seeking strategic alliances to tap into China’s rapidly advancing life sciences market and accelerate the development of next-generation therapies.